Background Bortezomib has been incorporated into DT-PACE (thalidomide, dexamethasone, cisplatin, doxorubicin, cyclophosphamide and etoposide) as an intensive regimen (VTD-PACE) prior to autologous stem cell transplantation for multiple myeloma (MM). We examined MM patients at our center who received ...
参考文献: Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients Eur J Haematol. 2022 Mar;108(3):178-189. doi: 10.1111/ejh.13723. Epub 20...
带串联移植的D-KRd在高风险TE NDMM患者中的可行性 多发性骨髓瘤（Multiple Myeloma，MM）是一种浆细胞恶性肿瘤，新诊断的多发性骨髓瘤（Newly Diagnosed Multiple Myeloma，NDMM）患者中存在不同的预后风险。高风险（High-Risk，HR）患者具有不良细胞遗传学特征，如del(17p)、t(4;14)或高危细胞遗传学异常，其生存...
参考来源: 1. Murielle Roussel , Valerie Lauwers-Cances , Soraya Wuilleme,et al. Up-front carfilzomib, lenalidomide, and dexamethasone with transplant for patients with multiple myeloma: the IFM KRd final results. Blood. 2021 Jul 15;138(...
[3] NCCN Guideline Version 1.2024. Multiple Myeloma. [4] Kumar SK, et al. 2022 ASH. Abstract 4559. [5] Dimopoulos MA, Špička I, Quach H, et al. Ixazomib as postinduc- tion maintenance for patients with newly diagnosed multiple my- eloma not undergoing autologous stem cell transplan...
Leypoldt LB, Tichy D, Besemer B, et al. Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Newly Diagnosed Multiple Myeloma. J Clin Oncol. 2023 Sep 27:JCO2301696. doi: 10.1200/JCO.23.01696. 责任编辑:CA-llx ...
New real-world data confirms that carfilzomib, lenalidomide, and dexamethasone (KRd) are a safe and effective option for patients with relapsed or refractory multiple myeloma. A new analysis of the carfilzomib-lenalidomide-dexamethasone (KRd) regimen in patients with relapsed/refractory multiple myeloma...
653.Myeloma/Amyloidosis: Therapy, excluding TransplantationVRd Versus KRd Safety Profiles in Newly Diagnosed Multiple Myeloma Patients Using Real-World Evidence Data from a Single Institution: VRd Has High Rates of Chronic Neuropathy, and KRd Has Low Rates of Cardiopulmonary or Renal Toxicities When ...
Lisa Leypoldt, MD, discusses findings from the phase 2 GMMG-CONCEPT trial in patients with multiple myeloma.
multiple myelomarelapsereal‐lifesafetyCarfilzomib–lenalidomide–dexamethasone (KRd) has been approved for the treatment of relapsed/refractory multiple myeloma (RRMM). We conducted a retrospective analysis of 197 RRMM patients (pts) between January 2016 and March 2018 in six Italian hematologic centers,...